Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Tiziana Life Sciences Ltd

TLSA · Nasdaq · CIK 0001723069 · Healthcare · Biotechnology

INSIDER SIGNAL

57.7 / 100

2 buyers · 5 purchase transaction lines · $1.0M gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeModerate
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+14.0 / 35
Purchase size+17.8 / 25
Role+13.0 / 20
Recency+2.9 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
  • ⚠ Role scores low · most senior buyer: Chief Executive Officer (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
CERRONE GABRIELE MDirector,TenPercentOwner
○●○●
Elrifi IvorChief Executive Officer
●●●○
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS2
PURCHASE CONCENTRATION94%Largest buyer: Elrifi Ivor · $985.9K
CLUSTER BUYING · 15D2 insidersPeak activity: 2026-07-21–2026-08-05

Roles in the peak window: Chief Executive Officer, Director,TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

57.7 / 100

Latest recorded score

↓ -0.1 ptsversus the previous recorded snapshot
  1. 58.0
  2. 58.0
  3. 57.9
  4. 57.8
  5. 57.7

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

5Purchases
0Sales
3Other Form 4 lines
7SEC filings · 365 days
BUYING5 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER3 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
+24.0%
3M
-10.5%
6M
+0.8%
12M
-48.0%

Volatility & liquidity

Volatility
94.7%
Beta
—
Avg daily value
USD 904,485

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
—
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
2,640,735
Previous report
1,733,862
Avg daily volume
824,539
Days to cover
3.2

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-05Elrifi IvorPurchase (P)COMMON STOCK237,616USD 1.00USD 237,616SEC filing ↗
2026-08-04Elrifi IvorPurchase (P)COMMON STOCK83,807USD 0.97USD 81,293SEC filing ↗
2026-08-03Elrifi IvorPurchase (P)COMMON STOCK667,000USD 1.00USD 667,000SEC filing ↗
2026-07-21CERRONE GABRIELE MPurchase (P)COMMON STOCK42,357USD 0.99USD 41,933SEC filing ↗
2026-06-12CERRONE GABRIELE MPurchase (P)COMMON STOCK15,000USD 1.11USD 16,650SEC filing ↗

Form 4 evidence

8 transaction lines in the latest 365-day window; 8 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-15Elrifi IvorOption exercise / conversion (M)COMMON STOCK1,050,000USD —USD —SEC filing ↗
2026-08-05Elrifi IvorPurchase (P)COMMON STOCK237,616USD 1.00USD 237,616SEC filing ↗
2026-08-04Elrifi IvorPurchase (P)COMMON STOCK83,807USD 0.97USD 81,293SEC filing ↗
Show recent Form 4 evidence (8 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-15Elrifi IvorOption exercise / conversion (M)COMMON STOCK1,050,000USD —USD —SEC filing ↗
2026-08-05Elrifi IvorPurchase (P)COMMON STOCK237,616USD 1.00USD 237,616SEC filing ↗
2026-08-04Elrifi IvorPurchase (P)COMMON STOCK83,807USD 0.97USD 81,293SEC filing ↗
2026-08-03Elrifi IvorPurchase (P)COMMON STOCK667,000USD 1.00USD 667,000SEC filing ↗
2026-07-21CERRONE GABRIELE MPurchase (P)COMMON STOCK42,357USD 0.99USD 41,933SEC filing ↗
2026-07-21CERRONE GABRIELE MAward / grant (A)COMMON STOCK42,357USD 0.99USD 41,933SEC filing ↗
2026-06-12CERRONE GABRIELE MPurchase (P)COMMON STOCK15,000USD 1.11USD 16,650SEC filing ↗
2026-06-12CERRONE GABRIELE MAward / grant (A)COMMON STOCK15,000USD 1.11USD 16,650SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerTLSA
CIK0001723069
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history8 transaction lines from 2026-06-12 to 2026-08-15
5 P purchase lines · 0 S sale lines · 3 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.